Publications
492
Citations
3,705
Est. group size
~45
Recurring co-author estimate
Active years
42
Publishing since 1985
Typically publishes in teams of ~16 · 1% small-team papers (≤3 authors) · across 21 venues
- Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Journal of Clinical Oncology · 2025
- Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study
Oral Oncology · 2025
- Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163
Clinical Cancer Research · 2025
- 1329MO Enfortumab vedotin plus pembrolizumab (EV + P) as first-line (1L) treatment in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Results from a cohort of the EV-202 trial
Annals of Oncology · 2025
- A phase II (Alliance/A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).
Journal of Clinical Oncology · 2025
- Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
JCO Precision Oncology · 2025
- Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus
Journal of Clinical Oncology · 2025
- Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma: 2-Year Follow-up and Biomarker Analyses
EJC Skin Cancer · 2025
- Abstract CT041: Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors
Cancer Research · 2025
- Data from Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163
2025
- Supplementary Table1 from Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163
2025
- Supplementary Materials1 from Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163
2025
- First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn
Translational Cancer Research · 2025
- Abstract A123: Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients
Molecular Cancer Therapeutics · 2025
- 1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)
Annals of Oncology · 2025
- International Journal of Radiation Oncology*Biology*Physics×34
- Journal of Clinical Oncology×26
- Oral Oncology×11
- Head & Neck×11
- Clinical Cancer Research×9
- Jennifer Shah
Medicine · University of Michigan
- Michelle Mierzwa
Medicine · University of Michigan
- Caitlin A. Schonewolf
Medicine · University of Michigan
- Keith Casper
Medicine · University of Michigan
- Catherine T. Haring
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile